Bempedoic Acid + Ezetimibe

Bempedoic acid plus ezetimibe is a single tablet that combines two cholesterol-lowering medicines with different mechanisms, sold under the brand names Nexlizet in the United States and Nustendi in Europe ^[1]. It is designed to lower low-density lipoprotein (LDL) cholesterol, and it offers a way to attack cholesterol on two fronts at once without adding a statin ^[1][3]. Both ingredients are non-statin agents, which makes the combination attractive for people who cannot tolerate statins or who need extra LDL reduction beyond what a statin alone provides ^[1].

The two drugs are complementary. Bempedoic acid inhibits ATP-citrate lyase, an enzyme early in the liver's cholesterol-synthesis pathway, reducing how much cholesterol the liver makes; because it is activated only in the liver and not in muscle, it rarely causes the muscle symptoms associated with statins ^[2]. Ezetimibe works in the gut, where it blocks a transport protein called Niemann-Pick C1-Like 1 that normally ferries cholesterol from the intestine into the body, thereby cutting the absorption of both dietary and bile-derived cholesterol ^[3]. By lowering cholesterol production and cholesterol absorption at the same time, the combination reduces LDL more than either component used on its own ^[3][4].

Clinical trials of the two agents together, including a fixed-dose combination study in patients at high cardiovascular risk already taking maximally tolerated statins, showed that adding bempedoic acid and ezetimibe produced substantial further reductions in LDL cholesterol ^[4]. Bempedoic acid on its own was also shown to lower LDL when added to ezetimibe in statin-intolerant patients ^[3], and comparative analyses rank such non-statin combinations among the effective options for driving LDL down ^[5]. The cardiovascular value of the bempedoic-acid component was later demonstrated in the large CLEAR Outcomes trial, which found reduced cardiovascular events in statin-intolerant patients ^[1]. The combination is used as an add-on to diet and, where appropriate, to statins, to help patients reach their LDL goals ^[1].

The fixed-dose combination was approved in 2020 by the U.S. Food and Drug Administration and the European Medicines Agency and is taken as an oral tablet ^[1]. Ezetimibe has a long record of good tolerability, while the bempedoic-acid component brings its own considerations, including a tendency to raise uric acid and provoke gout and an association with tendon rupture ^[1]. As a prescription medicine used to manage cardiovascular risk, it is prescribed and monitored by a clinician ^[1].

This prescription combination carries the profiles of both drugs. From bempedoic acid come raised uric acid with possible gout, elevated liver enzymes, a small creatinine rise, and a signal for tendon injury. Ezetimibe is usually very well tolerated, with occasional diarrhea, muscle aches or a rise in liver enzymes, particularly when a statin is also on board. If a statin is added, simvastatin and pravastatin doses must be capped. It should be avoided in pregnancy and breastfeeding, and liver tests and uric acid are worth monitoring.

This fixed-dose combination pairs two established non-statin therapies with complementary mechanisms: bempedoic acid, developed by Esperion Therapeutics to inhibit ATP-citrate lyase in the liver, and ezetimibe, an intestinal cholesterol-absorption inhibitor discovered by Schering-Plough and first approved in 2002. Recognizing that blocking cholesterol synthesis and cholesterol absorption together lowers LDL more than either alone, developers combined the two into a single tablet. The United States FDA approved the combination in February 2020 under the brand name Nexlizet, with European approval as Nustendi following the same year. Its arrival gave clinicians a convenient once-daily option for patients needing greater LDL reduction, particularly those unable to tolerate statins.

The bempedoic acid and ezetimibe combination is regarded as a thoughtful piece of drug design, bringing together two well-understood non-statin mechanisms in one pill to achieve LDL reductions that neither reaches alone. It has been especially welcomed for statin-intolerant patients and for those who remain above target despite maximally tolerated statin therapy, filling a real gap in lipid management. Clinicians appreciate the simplicity of a single daily tablet, which can support adherence in people who would otherwise juggle multiple prescriptions. Because the cardiovascular outcome evidence rests largely on the bempedoic acid component, prescribers view it as a practical intensification step, and they remain mindful of bempedoic acid's tendency to raise uric acid.